Bionik Laboratories (BNKL) 10-Q 12 Aug 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2020	Aug. 12, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	0001508381
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Trading Symbol	BNKL
Entity Common Stock, Shares Outstanding		5,009,151
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Small Business	true

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Current
Cash and cash equivalents	$ 2,403,037	$ 2,269,747
Accounts receivable, net of allowance for doubtful accounts of $Nil (March 31, 2020 - $167,500)	975,272	846,964
Prepaid expenses and other receivables (Note 5)	1,723,353	1,632,555
Inventories (Note 6)	944,990	1,059,462
Due from related parties (Note 9(a))	18,657	17,840
Total Current Assets	6,065,309	5,826,568
Equipment (Note 7)	136,032	154,144
Technology and other assets (Note 4)	1,426,420	1,449,924
Goodwill (Note 3)	11,085,984	11,085,984
Total Assets	18,713,745	18,516,620
Current
Accounts Payable (Notes 9(b))	443,874	857,093
Accrued liabilities (Notes 8 and 9(b))	2,057,784	1,647,656
PPP Loan (Note 8 (c))	459,912	0
Convertible Loans (Note 8(a) (b))	3,452,680	2,078,833
Deferred revenue - Contract Liabilities	582,281	616,063
Total Current Liabilities	6,996,531	5,199,645
Shareholders' Equity
Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2020 - 1)	0	0
Common Shares, par value $0.001; Authorized - 500,000,000; Issued and outstanding 5,009,151 and 117,683 Exchangeable Shares (March 31, 2020 5,009,151 and 117,683 Exchangeable Shares)	5,126	5,126
Additional paid in capital	85,050,885	84,643,570
Deficit	(73,380,946)	(71,373,870)
Accumulated other comprehensive income	42,149	42,149
Total Shareholders' Equity	11,717,214	13,316,975
Total Liabilities and Shareholders' Equity	$ 18,713,745	$ 18,516,620

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Allowance for Doubtful Accounts Receivable, Current	$ 0	$ 167,500
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	5,009,151	5,009,151
Common Stock, Shares, Outstanding	5,009,151	5,009,151
Common Stock, Other Shares, Issued	117,683	117,683
Special Voting [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1	1
Preferred Stock, Shares Issued	1	1
Preferred Stock, Shares Outstanding	1	1

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss
Sales	$ 257,908	$ 790,379
Cost of Sales	62,555	336,085
Gross Margin	195,353	454,294
Operating expenses
Sales and marketing	223,185	583,732
Research and development	353,263	816,523
General and administrative	1,128,510	841,693
Share-based compensation expense (Notes 11)	407,315	287,757
Amortization (Note 4)	23,504	69,314
Depreciation (Note 7)	18,112	23,970
Total operating expenses	2,153,889	2,622,989
Other (income) expenses
Other expense	74,975	14,296
Other income	(37,612)	0
Foreign exchange	11,177	(62,347)
Total other income (expenses)	48,540	(48,051)
Net loss and comprehensive loss for the period	$ (2,007,076)	$ (2,120,644)
Loss per share - basic and diluted	$ (0.39)	$ (0.55)
Weighted average number of shares outstanding - basic and diluted	5,126,834	3,858,637

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity - USD ($)	Special Voting [Member]	Common Shares [Member]	Additional Paid in Capital [Member]	Deficit [Member]	Comprehensive Income [Member]	Total
Opening Balance at Mar. 31, 2019	$ 0	$ 3,858	$ 73,719,299	$ (46,357,373)	$ 42,149	$ 27,407,933
Opening Balance (in shares) at Mar. 31, 2019	1	3,858,637
Share compensation expense	$ 0	$ 0	287,757	0	0	287,757
Share compensation expense (in shares)	0	0
Net loss for the year	$ 0	$ 0	0	(2,120,644)	0	(2,120,644)
Closing Balance at Jun. 30, 2019	$ 0	$ 3,858	74,007,056	(48,478,017)	42,149	25,575,046
Closing Balance (in shares) at Jun. 30, 2019	1	3,838,637
Opening Balance at Mar. 31, 2019	$ 0	$ 3,858	73,719,299	(46,357,373)	42,149	27,407,933
Opening Balance (in shares) at Mar. 31, 2019	1	3,858,637
Closing Balance at Mar. 31, 2020	$ 0	$ 5,126	84,643,570	(71,373,870)	42,149	13,316,975
Closing Balance (in shares) at Mar. 31, 2020	1	5,126,834
Opening Balance at Jun. 30, 2019	$ 0	$ 3,858	74,007,056	(48,478,017)	42,149	25,575,046
Opening Balance (in shares) at Jun. 30, 2019	1	3,838,637
Share compensation expense	$ 0	$ 0	1,493,855	0	0	1,493,855
Share compensation expense (in shares)	0	0
Conversion of Promissory Note	$ 0	$ 1,268	9,142,659	0	0	9,143,927
Conversion of Promissory Note (in shares)	0	1,268,191
Net loss for the year	$ 0	$ 0	0	(22,895,853)	0	(22,895,853)
Adjustment due to 1:150 share consolidation round-up	$ 0	$ 0	0	0	0	0
Adjustment due to 1:150 share consolidation round-up (in shares)	0	6
Closing Balance at Mar. 31, 2020	$ 0	$ 5,126	84,643,570	(71,373,870)	42,149	13,316,975
Closing Balance (in shares) at Mar. 31, 2020	1	5,126,834
Share compensation expense	$ 0	$ 0	407,315	0	0	407,315
Net loss for the year	0	0	0	(2,007,076)	0	(2,007,076)
Closing Balance at Jun. 30, 2020	$ 0	$ 5,126	$ 85,050,885	$ (73,380,946)	$ 42,149	$ 11,717,214
Closing Balance (in shares) at Jun. 30, 2020	1	5,126,834

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities
Net loss for the period	$ (2,007,076)	$ (2,120,644)
Adjustment for items not affecting cash
Depreciation	18,112	23,970
Amortization	23,504	69,314
Interest expense	74,975	13,283
Share based compensation expense	407,315	287,757
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	(1,483,170)	(1,726,320)
Changes in non-cash working capital items
Accounts receivable	(128,308)	496,181
Prepaid expenses and other receivables	(90,798)	160,305
Due from related parties	(817)	(483)
Inventories	114,472	(176,376)
Accounts payable	(413,219)	(93,835)
Accrued liabilities	406,425	(41,434)
Deferred revenue	(33,782)	58,016
Net cash (used in) operating activities	(1,629,197)	(1,323,946)
Investing activities
Acquisition of equipment	0	(42,802)
Net cash (used in) investing activities	0	(42,802)
Financing activities
Proceeds from convertible loans	1,302,575	950,000
Proceeds from PPP Loan	459,912	0
Proceeds from term loan	0	500,000
Net cash provided by financing activities	1,762,487	1,450,000
Net increase in cash and cash equivalents for the period	133,290	83,252
Cash and cash equivalents, beginning of the period	2,269,747	2,269,747
Cash and cash equivalents, end of the period	$ 2,403,037	$ 530,031

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN	3 Months Ended
	Jun. 30, 2020
NATURE OF OPERATIONS AND GOING CONCERN
NATURE OF OPERATIONS AND GOING CONCERN	1. NATURE OF OPERATIONS AND GOING CONCERN The Company and its Operations Bionik Laboratories Corp. (the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On October 29, 2018, the Company implemented at 1 for 150 reverse stock-split of the common and exchangeable shares. On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”) and Bionik Canada issued 333,334 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition, the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 10). On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (IMT), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (Bionik Mergerco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 157,667 shares of the Company’s common stock (Note 4). On November 6, 2017, the Company approved an increase in its authorized shares of common stock to 250,000,000 from 150,000,000, and on June 12, 2018, the Company approved an increase in its authorized shares of common stock to 500,000,000 from 250,000,000. References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Inc., Bionik Acquisition Inc. and Bionik Canada. The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA 02472. Going Concern As at June 30, 2020, the Company had a working capital deficit of $931,222 (March 31, 2020 - working capital of $626,923) and an accumulated deficit of $(73,380,946) (March 31, 2020 $(71,373,870)) and the Company incurred a net loss and comprehensive loss of $(2,007,076) for the three month period ended June 30, 2020 (June 30, 2019 – $(2,120,644). There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing to fund its operations and it is currently working on securing this funding through corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations. The Company expects to raise additional funds to meet the Company’s anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these consolidated financial statements.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Jun. 30, 2020
BASIS OF PRESENTATION
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION During the 2019 fiscal year, holders of the common stock and exchangeable shares of the Company approved, through a majority shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Bionik’s common stock and exchangeable shares at a ratio up to one-to-one hundred and fifty. The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2020 and through the date of this report filing.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jun. 30, 2020
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	3. SIGNIFICANT ACCOUNTING POLICIES Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10‑K for the year ended March 31, 2020. The interim disclosures generally do not repeat those in the annual statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. The changes in accounting policies in the Company’s unaudited condensed consolidated interim financial statements from the March 31, 2020 audited financial statements are described below. Newly Adopted and Recently Issued Accounting Pronouncements Newly Adopted In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after December 31, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date and the Company does not expect this policy will have a material effect on the consolidated balance sheet or consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. The Company has adopted ASU 2017-04 and it did not have a material effect on the consolidated balance sheet and consolidated statement of operations. In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which introduces an expected credit loss methodology for the impairment of financial assets measured at amortized cost basis. The methodology replaces the probable, incurred loss model for those assets. The update if effective for fiscal years beginning after December 15, 2019. The Company has adopted ASU 2016-13 and it did not have a material effect on the consolidated balance sheet and consolidated statement of operations. Recently issued Accounting Standards Update 2020-06—Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity: simplifies accounting for convertible instruments by removing major separation models required under current Generally Accepted Accounting Principles (GAAP). Consequently, more convertible debt instruments will be reported as a single liability instrument and more convertible preferred stock as a single equity instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted earnings per share (EPS) calculation in certain areas. The amendments in this Update are effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is assessing the impact that the adoption of ASU 2020-06 will have on the consolidated balance sheet and consolidated statement of operations. Canada Emergency Wage Subsidy (CEWS) CEWS is recognized as other income in the consolidated statement of operations in the period in which the Company recognizes expenses for which CEWS is intended to compensate. Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the condensed consolidated interim balance sheets and amounted to $81,225 at June 30, 2020 (March 31, 2020 - $162,449). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $Nil of expenses related to warranty expenses. Additionally, the Company reversed $81,224 of its warranty provision due to low warranty claims and recorded this expense and reversal in cost of goods sold for the three-month period ended June 30, 2020 (June 30, 2019 – $26,911).

TECHNOLOGY AND OTHER ASSETS

TECHNOLOGY AND OTHER ASSETS	3 Months Ended
	Jun. 30, 2020
TECHNOLOGY AND OTHER ASSETS
TECHNOLOGY AND OTHER ASSETS	4. TECHNOLOGY AND OTHER ASSETS The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the three months ended June 30, 2020, and the year ended March 31, 2020: Value Impairment Expenses Value at Expenses Value at Amortization acquired March 31, 2020 March 31, 2020 June 30, 2020 June 30, 2020 Intangible assets acquired period (years) $ $ $ $ $ $ Patents and exclusive License Agreement 1,306,031 307,388 469,962 20,277 449,685 Trademark Indefinite 2,505,907 1,605,907 — 900,000 — 900,000 Customer relationships 1,431,680 787,245 79,962 3,227 76,735 Non compete agreement 61,366 — — — — — Assembled workforce 275,720 — — — — — 5,580,704 2,700,540 1,449,924 23,504 1,426,420 The cumulative amortization for the technology and other assets was $1,453,744 at June 30, 2020 (March 31, 2020- $1,430,240).

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	3 Months Ended
	Jun. 30, 2020
PREPAID EXPENSES AND OTHER RECEIVABLES
PREPAID EXPENSES AND OTHER RECEIVABLES	5. PREPAID EXPENSES AND OTHER RECEIVABLES June 30, March 31, 2020 2020 $ $ Prepaid expenses and other receivables 34,272 78,816 Prepaid inventory 1,499,042 1,450,024 Prepaid insurance 176,928 57,226 Sales taxes receivable (i) 13,111 46,489 1,723,353 1,632,555

INVENTORIES

INVENTORIES	3 Months Ended
	Jun. 30, 2020
INVENTORIES
INVENTORIES	6. INVENTORIES June 30, March 31, 2020 2020 $ $ Finished Goods 944,990 1,059,462 During the three-month period ended June 30, 2020, the Company expensed $143,810 in inventory as cost of goods sold (June 30, 2019 - $299,795) offset by a warranty adjustment of $81,224. The Company no longer maintains a raw materials inventory as it has outsourced its manufacturing to a third party.

EQUIPMENT

EQUIPMENT	3 Months Ended
	Jun. 30, 2020
EQUIPMENT
EQUIPMENT	7. EQUIPMENT Equipment consisted of the following as at June 30, 2020 and March 31, 2020: June 30, 2020 March 31, 2020 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 303,337 269,174 34,163 303,337 264,520 38,817 Furniture and fixtures 36,795 31,240 5,555 36,795 30,953 5,842 Demonstration equipment 135,543 49,395 86,148 135,543 37,662 97,881 Manufacturing equipment 88,742 86,789 1,953 88,742 86,688 2,054 Tools and parts 11,422 7,813 3,609 11,422 7,627 3,795 Assets under capital lease 23,019 18,415 4,604 23,019 17,264 5,755 598,858 462,826 136,032 598,858 444,714 154,144 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the three-month period ended June 30, 2020 was $18,112 (June 30, 2019 - $23,970).

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Jun. 30, 2020
NOTES PAYABLE
NOTES PAYABLE	8. NOTES PAYABLE (a) Convertible Loans Payable During the quarter ended June 30, 2020, the Company received $1,302,575, in addition to $70,000 previously loaned to the Company, pursuant to a $3,000,000 (later increased to $7,000,000) convertible note offering. The convertible notes bear interest at a fixed rate at 1% per month. The convertible loans will be convertible into equity of the Company upon the following events on the following terms: (i) On the Maturity Date, the outstanding principal and accrued and unpaid interest under the convertible note will be converted into shares of common stock at a conversion price of $8.55 per shares in the event of an investment on or prior to December 31, 2019, and $9.50 per share in the event of an investment after December 31, 2019 (the “Conversion Price”). (ii) Upon a change of control transaction prior to the Maturity Date, the outstanding principal and accrued and unpaid interest under the convertible notes would, at the election of the holders of a majority of the outstanding principal of the loans under the offering, be either (i) payable upon demand as of the closing of such change of control transaction or (ii) convertible into shares of the Company’s common stock immediately prior to such change of control transaction at a price per share equal to the lesser of (x) the Conversion Price or (y) the per share consideration to be received by the holders of the common stock in such change of control transaction. In the event the Company raises capital through the sale of Common Stock for cash during the period ending on the three year anniversary of the issuance date of the convertible notes, and the price per share thereof (the “Offering Price”) minus 20% is less than the original Conversion Price, then in such event the Company shall issue to all convertible loan holder at, at no further cost, additional shares of common stock equal to the number of conversion shares the holders would have received upon conversion if the Conversion Price equaled to a 20% discount to the Offering Price, less the number of shares of conversion shares actually issued on or as of the Maturity Date. Since the Company has early adopted ASU 2017-11, the anti-dilution protection clause does not contribute to the conversion feature to be a derivative liability. The interest accrued on these convertible loans for the period ended June 30, 2020 was $15,588 (March 31, 2020- $4,317). (b) Short term loan On March 23, 2020, the Company received a $2,000,000 loan from an existing shareholder. The promissory note bears interest at a fixed rate of 1% per month and has a maturity date of the earlier of (i) March 31, 2022 and (ii) the date of receipt of a minimum of US$5,000,000 from a “Subsequent Financing.” The accrued interest shall be payable one-half at the maturity date, and one-half on a quarterly basis as follows: (a) the quarterly interest payments shall be payable in cash commencing on the six month anniversary of the issue date (or the nine month anniversary of the issue date if as of such six month anniversary the World Health Organization (or a corresponding government or government agency) still categorizes or deems COVID-19 or the novel corona virus as a pandemic or outbreak) (the “First Interest Payment Date”), with the quarterly payments accruing for the first (or first two, as the case may be) interest payment dates nevertheless being payable, without further interest thereon, pro rata from the First Interest Payment Date through the maturity date. The loan is repayable or convertible to common shares at the loan holder’s option. Interest accrued on this loan at June 30, 2020 is $64,516(March 31, 2020- $4,516). (c) PPP Loan On May 1, 2020, the Company signed a Promissory Note for $459,912 pursuant to the federal Paycheck Protection Program under the Coronavirus Aid, Relief and Economic Security Act, which is administered by the U.S. Small Business Administration. The loan is unsecured, bears interest of 1% per annum and a deferment period of 6 months. The loan is to be used primarily for payroll related costs, lease and utility payments. The Company intends to apply for forgiveness for all or a portion of the loans in accordance with applicable law. If the loan is not forgiven, the Company will be obligated to repay the loan during the period of 2 years.

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	3 Months Ended
	Jun. 30, 2020
RELATED PARTY TRANSACTIONS AND BALANCES
RELATED PARTY TRANSACTIONS AND BALANCES	9. RELATED PARTY TRANSACTIONS AND BALANCES (a) Due from related parties At June 30, 2020 there was an outstanding loan to the Chief Technology Officer (“CTO”) of the Company of 18,657(March 31, 2020 – $17,840).The loan has an Interest rate of 2% based on the Canada Revenue Agency’s prescribed rate for such advances and is denominated in Canadian dollars. During the period ended June 30, 2020, the Company accrued interest receivable in the amount of $90 (March 31, 2020 – $472); the remaining fluctuation in the balance from the prior year is due to changes in foreign exchange. (b) Accounts payable and accrued liabilities As at June 30, 2020, $193,285 (March 31, 2020 – $30,866 ) was owing to the CEO of the Company; $57,246 (March 31, 2020 – $9,464) was owing to the Chief Technology Officer; $70,963 (March 31, 2020 – $1,827 )was owing to the Chief Financial Officer (“CFO”), $32,472 (March 31, 2020 - $Nil) was owing to the Chief Commercial Officer (“CCO”), all related to bonuses and business expenses.

SHARE CAPITAL

SHARE CAPITAL	3 Months Ended
	Jun. 30, 2020
SHARE CAPITAL
SHARE CAPITAL	10. SHARE CAPITAL June 30, 2020 March 31, 2020 Number of Number of shares $ shares $ Exchangeable Shares Balance beginning of period 117,683 118 196,799 197 Converted into common shares (a) — — (79,116) (79) Balance at end of period 117,683 118 117,683 118 Common Shares Balance at beginning of the period 5,009,151 5,008 3,661,838 3,661 Shares issued to exchangeable shareholders (a) — — 79,116 79 Shares issued on conversion of loans — — 1,268,191 1,268 Share consolidation rounding adjustment — — 6 — Balance at end of the period 5,009,151 5,008 5,009,151 5,008 TOTAL SHARES 5,126,834 5,126 5,126,834 5,126 (a) During the quarter ended June 30, 2020, Nil exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2020 – 79,116 shares) Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation and is not convertible into shares of common stock of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement and the Special Voting Preferred Share will be automatically cancelled.

STOCK OPTIONS

STOCK OPTIONS	3 Months Ended
	Jun. 30, 2020
STOCK OPTIONS
STOCK OPTIONS	11. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. On September 1, 2017, the Company granted 81,436 options at $24.15 per share equally to an executive officer and a consultant, who is now the Chairman of the Company. 27,148 options have vested and 50% of the remaining options vest on performance being met and 50% vest annually over 5 years for the CEO, for our Chairman the options vest over 5 years. The grant date fair value was $1,832,304 and $57,259 is the current expense for the quarter ended June 30, 2020 (June 30, 2019 - $57,259). On January 24, 2018, the Company granted 24,267 options at $23.25 per share to employees that vest equally on January 24, 2019, 2020 and 2021. 7,334 options were cancelled for the year ended March 31, 2019 and 266 for the three-month period ended June 30, 2020. The grant fair value was $491,036 and $28,554 is the current stock compensation expense for the quarter ended June 30, 2020 (June 30, 2019 - $28,554). On May 31, 2019 169,882 options were issued to employees and directors of the Company with an exercise price of $3.16 per share that vest over 1 year and 6 months, of which one-third immediately vest and one-third vest over each of the next two 6-month periods. The options expire in 7 years. The options were valued using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk-free rate of 1.59%. The grant fair value was $453,585 and $50,755 of stock compensation was recognized for the quarter ended June 30, 2020. On July 26, 2019, 484,612 options were granted to employees and consultants at an exercise price of $3.595. The options were using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk-free rate of 1.59%. The grant fair value was $1,525,525. 11,461 options were cancelled for the year ended March 31, 2020 and 1,286 were canceled and stock compensation of $269,579 was recognized in the quarter ended June 30, 2020. On September 3, 2019, 5,000 options were granted to an employee at an exercise price of $3.20 which will vest over three years starting September 3, 2020. The options were valued using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk-free rate of 1.59%. The grant fair value was $14,010 and $1,168 of stock compensation expense was recognized in the quarter ended June 30, 2020. During the quarter ended June 30, 2020, the Company recorded $407,315 in share-based compensation related to the vesting of stock options (June 30, 2019 – $287,757). The following is a summary of stock options outstanding and exercisable as of June 30, 2020: Exercise Price ($) Number of Options Expiry Date Exercisable Options 34.500 630 20-Jun-21 630 34.500 13,212 01-Jul-21 13,212 34.500 944 17-Feb-22 944 183.000 2,667 24-Nov-22 2,667 150.000 11,400 14-Dec-22 11,400 142.500 359 28-Mar-23 359 157.500 1,387 28-Mar-23 1,387 105.000 2,667 06-Feb-24 2,667 102.000 1,667 13-Feb-24 1,667 142.500 106 03-Mar-24 106 157.500 408 03-Mar-24 408 142.500 43 14-Mar-24 43 157.500 164 14-Mar-24 164 142.500 327 30-Sep-24 327 157.500 1,264 30-Sep-24 1,264 24.150 81,436 01-Sep-27 40,722 23.250 13,064 24-Jan-25 9,132 9.735 40,000 19-Apr-28 40,000 3.16 168,283 31-May-26 168,283 3.595 473,151 26-July-26 56,417 3.20 5,000 03-Sep-26 — 818,179 351,798 The weighted-average remaining contractual term of the outstanding options is 6.02 years (March 31, 2020 – 6.28 years) and for the options that are exercisable the weighted average is 5.84 years (March 31, 2020 – 6.12 years).

WARRANTS

WARRANTS	3 Months Ended
	Jun. 30, 2020
WARRANTS
WARRANTS	12. WARRANTS The following is a continuity schedule of the Company’s common share purchase warrants: Weighted Average Number of Exercise Price Warrants ($) Outstanding and exercisable, March 31, 2019 288,517 40.27 Expired (163,483) (38.91) Outstanding and exercisable, March 31, 2020 125,034 20.07 Expired (2,667) (37.50) Outstanding and exercisable June 30, 2020 122,367 19.69 During the quarter ended June 30, 2020, 2,667 warrants expired in accordance with their terms. Common share purchase warrants The following is a summary of common share purchase warrants outstanding as of June 30, 2020. Exercise Number of Price ($) Warrants Expiry Date 90.00 15,658 March 31, 2023 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 122,367 The weighted-average remaining contractual term of the outstanding warrants was 2.07.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 30, 2020
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	13. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments (a) On February 25, 2015, 1,753 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan, the Company's then-CTO and COO had transferred 2,098 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the former CTO and COO 2,134 common shares. As at June 30, 2020 these shares have not yet been issued. (b) On May 17, 2017, the Company entered into a Co-operative Joint Venture Contract (the “JV Contract”) with Ginger Capital Investment Holding, Ltd. (the “JV Partner”) to form China Bionik Medical Rehabilitation Technology Ltd. (“China JV”), pursuant to which, among other things, the Company was to have a 25% interest and the JV Partner a 75% interest. The Company applied the equity method of accounting to the joint venture. The Company gave notice on May 18, 2020 to the JV Partner of the termination of the China JV as well as terminating the Licensing and Distribution agreements with the China JV. As a result of the termination of the China JV and related commercial agreements, the Company has been communicating with its counterparts regarding such termination. (c) In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, with a former director as a co-licenser, pursuant to which the Company pays the director and the co-licenser an aggregate royalty of 1% of sales based on patent #8,613,691. No sales have been made, as the technology under this patent has not been commercialized.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jun. 30, 2020
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	14. SUBSEQUENT EVENTS (a)

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jun. 30, 2020
SIGNIFICANT ACCOUNTING POLICIES
Unaudited Condensed Consolidated Interim Financial Statements	Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10‑K for the year ended March 31, 2020. The interim disclosures generally do not repeat those in the annual statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. The changes in accounting policies in the Company’s unaudited condensed consolidated interim financial statements from the March 31, 2020 audited financial statements are described below.
Newly Adopted and Recently Issued Accounting Pronouncements	Newly Adopted and Recently Issued Accounting Pronouncements Newly Adopted In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after December 31, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date and the Company does not expect this policy will have a material effect on the consolidated balance sheet or consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. The Company has adopted ASU 2017-04 and it did not have a material effect on the consolidated balance sheet and consolidated statement of operations. In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which introduces an expected credit loss methodology for the impairment of financial assets measured at amortized cost basis. The methodology replaces the probable, incurred loss model for those assets. The update if effective for fiscal years beginning after December 15, 2019. The Company has adopted ASU 2016-13 and it did not have a material effect on the consolidated balance sheet and consolidated statement of operations.
Recently Issued	Recently issued Accounting Standards Update 2020-06—Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity: simplifies accounting for convertible instruments by removing major separation models required under current Generally Accepted Accounting Principles (GAAP). Consequently, more convertible debt instruments will be reported as a single liability instrument and more convertible preferred stock as a single equity instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted earnings per share (EPS) calculation in certain areas. The amendments in this Update are effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is assessing the impact that the adoption of ASU 2020-06 will have on the consolidated balance sheet and consolidated statement of operations.
Canada Emergency Wage Subsidy (CEWS)	Canada Emergency Wage Subsidy (CEWS) CEWS is recognized as other income in the consolidated statement of operations in the period in which the Company recognizes expenses for which CEWS is intended to compensate.
Warranty Reserve and Deferred Warranty Revenue	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the condensed consolidated interim balance sheets and amounted to $81,225 at June 30, 2020 (March 31, 2020 - $162,449). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $Nil of expenses related to warranty expenses. Additionally, the Company reversed $81,224 of its warranty provision due to low warranty claims and recorded this expense and reversal in cost of goods sold for the three-month period ended June 30, 2020 (June 30, 2019 – $26,911).

TECHNOLOGY AND OTHER ASSETS (Ta

TECHNOLOGY AND OTHER ASSETS (Tables)	3 Months Ended
	Jun. 30, 2020
TECHNOLOGY AND OTHER ASSETS
Schedule of intangible assets acquired in the IMT acquisition	The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the three months ended June 30, 2020, and the year ended March 31, 2020: Value Impairment Expenses Value at Expenses Value at Amortization acquired March 31, 2020 March 31, 2020 June 30, 2020 June 30, 2020 Intangible assets acquired period (years) $ $ $ $ $ $ Patents and exclusive License Agreement 1,306,031 307,388 469,962 20,277 449,685 Trademark Indefinite 2,505,907 1,605,907 — 900,000 — 900,000 Customer relationships 1,431,680 787,245 79,962 3,227 76,735 Non compete agreement 61,366 — — — — — Assembled workforce 275,720 — — — — — 5,580,704 2,700,540 1,449,924 23,504 1,426,420

PREPAID EXPENSES AND OTHER RE_2

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	3 Months Ended
	Jun. 30, 2020
PREPAID EXPENSES AND OTHER RECEIVABLES
Schedule of prepaid expenses and other receivables	June 30, March 31, 2020 2020 $ $ Prepaid expenses and other receivables 34,272 78,816 Prepaid inventory 1,499,042 1,450,024 Prepaid insurance 176,928 57,226 Sales taxes receivable (i) 13,111 46,489 1,723,353 1,632,555

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Jun. 30, 2020
INVENTORIES
Schedule of inventory	June 30, March 31, 2020 2020 $ $ Finished Goods 944,990 1,059,462

EQUIPMENT (Tables)

EQUIPMENT (Tables)	3 Months Ended
	Jun. 30, 2020
EQUIPMENT
Schedule of components of equipment	Equipment consisted of the following as at June 30, 2020 and March 31, 2020: June 30, 2020 March 31, 2020 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 303,337 269,174 34,163 303,337 264,520 38,817 Furniture and fixtures 36,795 31,240 5,555 36,795 30,953 5,842 Demonstration equipment 135,543 49,395 86,148 135,543 37,662 97,881 Manufacturing equipment 88,742 86,789 1,953 88,742 86,688 2,054 Tools and parts 11,422 7,813 3,609 11,422 7,627 3,795 Assets under capital lease 23,019 18,415 4,604 23,019 17,264 5,755 598,858 462,826 136,032 598,858 444,714 154,144

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	3 Months Ended
	Jun. 30, 2020
SHARE CAPITAL
Schedule of share capital	June 30, 2020 March 31, 2020 Number of Number of shares $ shares $ Exchangeable Shares Balance beginning of period 117,683 118 196,799 197 Converted into common shares (a) — — (79,116) (79) Balance at end of period 117,683 118 117,683 118 Common Shares Balance at beginning of the period 5,009,151 5,008 3,661,838 3,661 Shares issued to exchangeable shareholders (a) — — 79,116 79 Shares issued on conversion of loans — — 1,268,191 1,268 Share consolidation rounding adjustment — — 6 — Balance at end of the period 5,009,151 5,008 5,009,151 5,008 TOTAL SHARES 5,126,834 5,126 5,126,834 5,126 (a) During the quarter ended June 30, 2020, Nil exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2020 – 79,116 shares)

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	3 Months Ended
	Jun. 30, 2020
STOCK OPTIONS
Schedule of stock options outstanding and exercisable	The following is a summary of stock options outstanding and exercisable as of June 30, 2020: Exercise Price ($) Number of Options Expiry Date Exercisable Options 34.500 630 20-Jun-21 630 34.500 13,212 01-Jul-21 13,212 34.500 944 17-Feb-22 944 183.000 2,667 24-Nov-22 2,667 150.000 11,400 14-Dec-22 11,400 142.500 359 28-Mar-23 359 157.500 1,387 28-Mar-23 1,387 105.000 2,667 06-Feb-24 2,667 102.000 1,667 13-Feb-24 1,667 142.500 106 03-Mar-24 106 157.500 408 03-Mar-24 408 142.500 43 14-Mar-24 43 157.500 164 14-Mar-24 164 142.500 327 30-Sep-24 327 157.500 1,264 30-Sep-24 1,264 24.150 81,436 01-Sep-27 40,722 23.250 13,064 24-Jan-25 9,132 9.735 40,000 19-Apr-28 40,000 3.16 168,283 31-May-26 168,283 3.595 473,151 26-July-26 56,417 3.20 5,000 03-Sep-26 — 818,179 351,798

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Jun. 30, 2020
WARRANTS
Schedule of continuity schedule	The following is a continuity schedule of the Company’s common share purchase warrants: Weighted Average Number of Exercise Price Warrants ($) Outstanding and exercisable, March 31, 2019 288,517 40.27 Expired (163,483) (38.91) Outstanding and exercisable, March 31, 2020 125,034 20.07 Expired (2,667) (37.50) Outstanding and exercisable June 30, 2020 122,367 19.69
Schedule of common share purchase warrants outstanding	The following is a summary of common share purchase warrants outstanding as of June 30, 2020. Exercise Number of Price ($) Warrants Expiry Date 90.00 15,658 March 31, 2023 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 122,367

NATURE OF OPERATIONS AND GOIN_2

NATURE OF OPERATIONS AND GOING CONCERN (Details)	Oct. 29, 2018	Apr. 21, 2016shares	Feb. 26, 2015shares	Feb. 25, 2015shares	Feb. 13, 2015	Jun. 30, 2020USD ($)shares	Jun. 30, 2019USD ($)	Mar. 31, 2020USD ($)shares	Jun. 12, 2018shares	Nov. 06, 2017shares	Mar. 31, 2017shares	Dec. 31, 2014shares
Common Stock, Shares Authorized						500,000,000		500,000,000	500,000,000	250,000,000	150,000,000	200,000,000
Reverse stock split ratio	0.0067				0.831105			0.0067
Stock Issued During Period, Shares, New Issues				1,753
Working Capital Surplus | $						$ 931,222		$ 626,923
Retained Earnings (Accumulated Deficit) | $						(73,380,946)		$ (71,373,870)
Comprehensive Income (Loss), Net of Tax | $						$ (2,007,076)	$ (2,120,644)
Interactive Motion Technologies, Inc. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		157,667
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues			333,334
Exchange ratio of exchangeable shares to common shares outstanding			3.14
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage			100.00%

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	Oct. 29, 2018	Feb. 13, 2015	Mar. 31, 2020
BASIS OF PRESENTATION
Stockholders' Equity Note, Stock Split, Conversion Ratio	0.0067	0.831105	0.0067

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Standard and Extended Product Warranty Accrual	$ 81,225		$ 162,449
Product Warranty Expense	0	$ 26,911
Reversal of warranty provision	$ 81,224

TECHNOLOGY AND OTHER ASSETS - I

TECHNOLOGY AND OTHER ASSETS - Intangible assets acquired (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 5,580,704
Impairment of Intangible Assets (Excluding Goodwill)	2,700,540
Amortization of Intangible Assets	23,504	$ 69,314	$ 277,258
Intangible Assets, Net (Excluding Goodwill)	$ 1,426,420		1,449,924
Patents and Exclusive License Agreement [Member]
Finite-Lived Intangible Asset, Useful Life	9 years 8 months 27 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,306,031
Impairment of Intangible Assets (Excluding Goodwill)	307,388
Amortization of Intangible Assets	20,277		134,090
Intangible Assets, Net (Excluding Goodwill)	$ 449,685		469,962
Trademark [Member]
Finite Lived Intangible Asset Useful Life Description	Indefinite
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 2,505,907
Impairment of Intangible Assets (Excluding Goodwill)	1,605,907
Amortization of Intangible Assets	0		0
Intangible Assets, Net (Excluding Goodwill)	$ 900,000		900,000
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life	10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,431,680
Impairment of Intangible Assets (Excluding Goodwill)	787,245
Amortization of Intangible Assets	3,227		143,168
Intangible Assets, Net (Excluding Goodwill)	$ 76,735		79,962
Non compete Agreement [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 61,366
Amortization of Intangible Assets	0		0
Intangible Assets, Net (Excluding Goodwill)	$ 0		0
Assembled Workforce [Member]
Finite-Lived Intangible Asset, Useful Life	1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 275,720
Amortization of Intangible Assets	0		0
Intangible Assets, Net (Excluding Goodwill)	$ 0		$ 0

TECHNOLOGY AND OTHER ASSETS - A

TECHNOLOGY AND OTHER ASSETS - Additional Information (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
TECHNOLOGY AND OTHER ASSETS
Technology and other assets cumulative amortization	$ 1,453,744	$ 1,430,240

PREPAID EXPENSES AND OTHER RE_3

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
PREPAID EXPENSES AND OTHER RECEIVABLES
Prepaid expenses and other receivables	$ 34,272	$ 78,816
Prepaid inventory	1,499,042	1,450,024
Prepaid insurance	176,928	57,226
Sales taxes receivable (i)	13,111	46,489
Total prepaid expenses and other receivables	$ 1,723,353	$ 1,632,555

INVENTORIES- Schedule of Invent

INVENTORIES- Schedule of Inventories (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
INVENTORIES
Finished Goods	$ 944,990	$ 1,059,462

INVENTORIES - Additional Inform

INVENTORIES - Additional Information (Details) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cost of Sales	$ 62,555	$ 336,085
Warranty adjustment	0	26,911
Inventory Cost [Member]
Cost of Sales	143,810	$ 299,795
Warranty adjustment	$ 81,224

EQUIPMENT - Schedule of net equ

EQUIPMENT - Schedule of net equipment (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Equipment [Line Items]
Equipment, Cost	$ 598,858	$ 598,858
Accumulated Depreciation	462,826	444,714
Equipment, Net	136,032	154,144
Computer and electronics [Member]
Equipment [Line Items]
Equipment, Cost	303,337	303,337
Accumulated Depreciation	269,174	264,520
Equipment, Net	34,163	38,817
Furniture and fixtures [Member]
Equipment [Line Items]
Equipment, Cost	36,795	36,795
Accumulated Depreciation	31,240	30,953
Equipment, Net	5,555	5,842
Demonstration equipment [Member]
Equipment [Line Items]
Equipment, Cost	135,543	135,543
Accumulated Depreciation	49,395	37,662
Equipment, Net	86,148	97,881
Manufacturing Equipment [Member]
Equipment [Line Items]
Equipment, Cost	88,742	88,742
Accumulated Depreciation	86,789	86,688
Equipment, Net	1,953	2,054
Tools and parts [Member]
Equipment [Line Items]
Equipment, Cost	11,422	11,422
Accumulated Depreciation	7,813	7,627
Equipment, Net	3,609	3,795
Assets under capital lease [Member]
Equipment [Line Items]
Equipment, Cost	23,019	23,019
Accumulated Depreciation	18,415	17,264
Equipment, Net	$ 4,604	$ 5,755

EQUIPMENT - Additional Informat

EQUIPMENT - Additional Information (Details) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
EQUIPMENT
Depreciation	$ 18,112	$ 23,970

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Jan. 01, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Proceeds from convertible loans	$ 1,302,575	$ 950,000
Convertible Loans Payable [Member]
Debt Instrument [Line Items]
Proceeds from convertible loans	1,302,575
Convertible loans received	70,000
Maximum Convertible note offering	$ 7,000,000		$ 3,000,000
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Discount Percentage On Offer Price	20.00%
Interest	$ 15,588		$ 4,317
Convertible Loans Payable with Conversion Price One [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price					$ 8.55
Convertible Loans Payable with Conversion Price Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price				$ 9.50

NOTES PAYABLE - Short term loan

NOTES PAYABLE - Short term loan (Details) - USD ($)	May 01, 2020	Mar. 23, 2020	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
Debt Instrument [Line Items]
Proceeds from short term loan		$ 2,000,000	$ 0	$ 500,000
Consummation of minimum of equity or debt financing			5,000,000
Interest accrued on loan			$ 64,516		$ 4,516
Promissory Note [Member]
Debt Instrument [Line Items]
Interest rate per month	1.00%	1.00%
Promissory Note signed	$ 459,912
Loan unsecured deferment period	6 months
Repayment of long term loan period	2 years

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020
RELATED PARTY TRANSACTIONS AND BALANCES
Accrued interest receivable	$ 90	$ 472
Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS AND BALANCES
Accounts Payable, Related Parties	193,285	30,866
Chief Technology Officer [Member]
RELATED PARTY TRANSACTIONS AND BALANCES
Due from Related Parties	$ 18,657	$ 17,840
Interest Rate On Loan	2.00%	2.00%
Accounts Payable, Related Parties	$ 57,246	$ 9,464
Chief Financial Officer [Member]
RELATED PARTY TRANSACTIONS AND BALANCES
Accounts Payable, Related Parties	70,963	1,827
Chief Commercial Officer [Member]
RELATED PARTY TRANSACTIONS AND BALANCES
Accounts Payable, Related Parties	$ 32,472	$ 0

SHARE CAPITAL - Common shares i

SHARE CAPITAL - Common shares issued (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2020
Opening Balance	$ 13,316,975	$ 25,575,046	$ 27,407,933
Shares issued to exchangeable shareholders (a)		9,143,927
Closing Balance	$ 11,717,214	$ 13,316,975	$ 13,316,975
Exchangeable Shares [Member]
Opening Balance (in shares)	117,683		196,799
Opening Balance	$ 118		$ 197
Converted into common shares (in shares)	0		(79,116)
Converted into common shares (a)	$ 0		$ (79)
Closing Balance (in shares)	117,683	117,683	117,683
Closing Balance	$ 118	$ 118	$ 118
Common Shares [Member]
Opening Balance (in shares)	5,009,151		3,661,838
Opening Balance	$ 5,008		$ 3,661
Shares issued to exchangeable shareholders (in shares)	0		79,116
Shares issued to exchangeable shareholders (a)	$ 0		$ 79
Shares issued on conversion of loans (in shares)	0		1,268,191
Shares issued on conversion of loans	$ 0		$ 1,268
Share consolidation rounding adjustment (in shares)	0		6
Share consolidation rounding adjustment (f)	$ 0		$ 0
Closing Balance (in shares)	5,009,151	5,009,151	5,009,151
Closing Balance	$ 5,008	$ 5,008	$ 5,008
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)	5,126,834
Opening Balance	$ 5,126
Closing Balance (in shares)	5,126,834	5,126,834	5,126,834
Closing Balance	$ 5,126	$ 5,126	$ 5,126

SHARE CAPITAL - Additional Info

SHARE CAPITAL - Additional Information (Details)	12 Months Ended
	Mar. 31, 2020shares
SHARE CAPITAL
Exchangeable Shares exchanged for common shares	79,116

STOCK OPTIONS - Summary of stoc

STOCK OPTIONS - Summary of stock options outstanding and exercisable (Details)	3 Months Ended
	Jun. 30, 2020$ / sharesshares
STOCK OPTIONS
Number of Options	818,179
Exercisable Options	351,798
Stock Option One [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 34.500
Number of Options	630
Expiry Date	Jun. 20, 2021
Exercisable Options	630
Stock Option Two [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 34.500
Number of Options	13,212
Expiry Date	Jul. 1, 2021
Exercisable Options	13,212
Stock Option Three [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 34.500
Number of Options	944
Expiry Date	Feb. 17, 2022
Exercisable Options	944
Stock Option Four [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 183
Number of Options	2,667
Expiry Date	Nov. 24, 2022
Exercisable Options	2,667
Stock Option Five [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 150
Number of Options	11,400
Expiry Date	Dec. 14, 2022
Exercisable Options	11,400
Stock Option Six [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 142.500
Number of Options	359
Expiry Date	Mar. 28, 2023
Exercisable Options	359
Stock Option Seven [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 157.500
Number of Options	1,387
Expiry Date	Mar. 28, 2023
Exercisable Options	1,387
Stock Option Eight [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 105
Number of Options	2,667
Expiry Date	Feb. 6, 2024
Exercisable Options	2,667
Stock Option Nine [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 102
Number of Options	1,667
Expiry Date	Feb. 13, 2024
Exercisable Options	1,667
Stock Option Ten [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 142.500
Number of Options	106
Expiry Date	Mar. 3, 2024
Exercisable Options	106
Stock Option Eleven [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 157.500
Number of Options	408
Expiry Date	Mar. 3, 2024
Exercisable Options	408
Stock Option Twelve [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 142.500
Number of Options	43
Expiry Date	Mar. 14, 2024
Exercisable Options	43
Stock Option Thirteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 157.500
Number of Options	164
Expiry Date	Mar. 14, 2024
Exercisable Options	164
Stock Option Fourteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 142.500
Number of Options	327
Expiry Date	Sep. 30, 2024
Exercisable Options	327
Stock Option Fifteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 157.500
Number of Options	1,264
Expiry Date	Sep. 30, 2024
Exercisable Options	1,264
Stock Option Sixteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 24.150
Number of Options	81,436
Expiry Date	Sep. 1, 2027
Exercisable Options	40,722
Stock Option Seventeen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 23.250
Number of Options	13,064
Expiry Date	Jan. 24, 2025
Exercisable Options	9,132
Stock Option Eighteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 9.735
Number of Options	40,000
Expiry Date	Apr. 19, 2028
Exercisable Options	40,000
Stock Option Nineteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 3.16
Number of Options	168,283
Expiry Date	May 31, 2026
Exercisable Options	168,283
Stock Option Twenty [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 3.595
Number of Options	473,151
Expiry Date	Jul. 26, 2026
Exercisable Options	56,417
Stock Option Twenty One [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 3.20
Number of Options	5,000
Expiry Date	Sep. 3, 2026
Exercisable Options	0

STOCK OPTIONS - Additional Info

STOCK OPTIONS - Additional Information (Details) - USD ($)	Sep. 03, 2019	Jul. 26, 2019	May 31, 2019	Jan. 24, 2018	Sep. 01, 2017	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Mar. 31, 2019
STOCK OPTIONS
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						818,179
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term						6 years 7 days		6 years 3 months 11 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term						5 years 10 months 2 days		6 years 1 month 13 days
Employee Stock Option [Member]
STOCK OPTIONS
Allocated Share-based Compensation Expense						$ 407,315	$ 287,757
Employees [Member]
STOCK OPTIONS
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period						266			7,334
Director and Employees [Member]
STOCK OPTIONS
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 3.16
Allocated Share-based Compensation Expense						$ 50,755
Grant fair value			$ 453,585
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			7 years
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			169,882
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			7 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			1.59%
Director and Employees [Member] | Minimum [Member]
STOCK OPTIONS
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			6 months
Director and Employees [Member] | Maximum [Member]
STOCK OPTIONS
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			1 year 6 months
Executive Employee And Consultant [Member]
STOCK OPTIONS
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					81,436
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 24.15
Allocated Share-based Compensation Expense						$ 57,259	57,259
Grant fair value					$ 1,832,304
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					27,148
Executive Employee And Consultant [Member] | Share-based Payment Arrangement, Tranche Two [Member]
STOCK OPTIONS
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					5 years
Employees and consultants [Member] | Employee Stock Option [Member]
STOCK OPTIONS
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		484,612
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 3.595
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period						1,286		11,461
Allocated Share-based Compensation Expense						$ 269,579
Grant fair value		$ 1,525,525
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		7 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.59%
Employee [Member]
STOCK OPTIONS
Allocated Share-based Compensation Expense						28,554	$ 28,554
Grant fair value				$ 491,036
Employee [Member] | Employee Stock Option [Member]
STOCK OPTIONS
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	5,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 3.20
Allocated Share-based Compensation Expense						$ 1,168
Grant fair value	$ 14,010
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	7 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Employees vest equally on January 24, 2019 [Member]
STOCK OPTIONS
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				24,267
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 23.25
Employees vest equally on January 24 2020 [Member]
STOCK OPTIONS
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				23.25
Employees vest equally on January 24 2021 [Member]
STOCK OPTIONS
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 23.25

WARRANTS - Summary of continuit

WARRANTS - Summary of continuity schedule (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020
WARRANTS
Number of Warrants, Outstanding and exercisable, Beginning balance	125,034	288,517
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance	$ 20.07	$ 40.27
Number of Warrants, Expired	(2,667)	(163,483)
Weighted-Average Exercise Price, Expired	$ (37.50)	$ (38.91)
Number of Warrants, Outstanding and exercisable, Ending balance	122,367	125,034
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 19.69	$ 20.07

WARRANTS - Summary of common sh

WARRANTS - Summary of common share purchase warrants outstanding (Details)	3 Months Ended
	Jun. 30, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Warrants	122,367
Warrant One [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price | $ / shares	$ 90
Class of Warrant or Right, Number of Warrants	15,658
Class Of Warrant Or Right Expiry Date	Mar. 31, 2023
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price | $ / shares	$ 9.375
Class of Warrant or Right, Number of Warrants	64,025
Class Of Warrant Or Right Expiry Date	Aug. 14, 2022
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price | $ / shares	$ 9.375
Class of Warrant or Right, Number of Warrants	42,684
Class Of Warrant Or Right Expiry Date	Mar. 31, 2022

WARRANTS - Additional Informati

WARRANTS - Additional Information (Details) - shares	3 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020
WARRANTS
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations	2,667	163,483
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	2 years 26 days

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($)	Feb. 25, 2015	Jun. 30, 2020	May 17, 2017
Stock Issued During Period, Shares, New Issues	1,753
Stock Issued During Period, Value, New Issues	$ 210,323
Loan received and repaid	$ 241,185
Percentage of Royalty on Sales		1.00%
China JV
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			25.00%
JV Partner | China JV
Equity Method Investment, Ownership Percentage			75.00%
Former Chief Technology Officer And New Chief Technology Officer [Member]
Stock Transferred To Lenders	2,098
Stock to be Reimbursed to Officers	2,134

SUBSEQUENT EVENTS - Additional

SUBSEQUENT EVENTS - Additional Information (Details)	Jul. 01, 2020USD ($)
Subsequent Event
Subsequent Event [Line Items]
Convertible loans received	$ 200,000